←Irritable Bowel Syndrome
Study register · detail Systematic Review · Irritable Bowel Syndrome · 2020

Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy.

Pandey et al. ·Complementary therapies in medicine Impact 3.2
No direction reported GRADE High
SampleSystematische Review
DesignSystematic Review
Summary

Narrative review on the endocannabinoid system (ECS) in irritable bowel syndrome and cannabis as a potential therapy. Emphasizes the role of the ECS in GI physiology and in functional disorders such as IBS; concrete clinical efficacy data for cannabis in IBS are NOT reported. Conclusion: further research on ECS-based IBS therapies required.

Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Authors
Pandey S, Kashif S, Youssef M, Sarwal S, Zraik H, Singh R, Rutkofsky IH
DOI 10.1016/j.ctim.2019.102242↗
Design: Systematic Review
Share
Abstract
Irritable bowel syndrome (IBS) global burden is underestimated despite its high prevalence. It's a gastrointestinal disease having obscure pathophysiology with multiple therapies yet unsatisfactory remedies. The Endocannabinoid system (ECS) of our body plays a key role in maintaining normal physiology of the gastrointestinal tract as well as involves abnormalities including functional diseases like IBS. This review highlights the importance of the Endocannabinoid system, its connections with the normal gastrointestinal functions and abnormalities like IBS. It also discusses the role of cannabis as medical therapy in IBS patients. A literature search for articles related to endocannabinoids in IBS and medical cannabis in PubMed and Google Scholar was conducted. The studies highlighted the significant participation of ECS in IBS. However, the breach in obtaining the promising therapeutic model for IBS needed further investigation in ECS and uncover other treatments for IBS. This review summarizes ECS, highlights the relationship of ECS with IBS and explores cannabis as a potential therapy to treat IBS.
Indication
Further studies on Irritable Bowel Syndrome
All studies →
A Bilbao et al. · 2022 · BMC Medicine
163 citations
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Mixed Systematische Review + Meta-Analyse

Umfassende pharmakologie-basierte SR über k=152 RCTs (n=12.123) zu medizinischen Cannabinoiden; für Reizdarm (irritable bowel syndrome) wird die Evidenz als 'insufficient' (unzureichend) bewertet — keine signifikanten therapeutischen Effekte nachgewiesen.

10.1186/s12916-022-02459-1 View study →
A Chang et al. · 2023 · Neurogastroenterology and motility
32 citations
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).
Mixed RCT

Phase-2b-RCT CAPTIVATE, n=273 IBS-D/IBS-C-Patienten, Olorinab (CB2-Vollagonist) 10/25/50 mg 3× täglich vs. Placebo über 12 Wochen. Primärer Endpunkt (Änderung durchschnittlicher Bauchschmerz-Score bis Woche 12) nicht erreicht. Prä-spezifizierte Subgruppe mit moderaten-schweren Schmerzen (Baseline-Score ≥6,5): Olorinab 50 mg (n=35) signifikant wirksamer als Placebo (n=30), p=0,014. Verträglichkeit vergleichbar mit Placebo, keine schweren unerwünschten Ereignisse.

10.1111/nmo.14539 View study →
A Utz et al. · 2024 · Zeitschrift fur Gastroenterologie
5 citations
Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review
Mixed Systematic Review

Systematische Übersicht zu phytotherapeutischen Empfehlungen in medizinischen Leitlinien für gastroenterologische Erkrankungen. Für Reizdarmsyndrom (IBS): 'starke Empfehlung' für Pfefferminzöl (insbesondere bei Schmerz und Flatulenz); 'Empfehlung' für STW-5, Tibetisches Padma Lax und warme Kümmelöl-Kompressen zur Symptomlinderung. Cannabis-basierte Medikamente können bei abdominalen Schmerzen und klinisch relevantem Appetitverlust erwogen werden, wenn Standardtherapie unwirksam oder kontraindiziert; sollten nicht bei akuter Entzündung im aktiven Morbus Crohn verwendet werden. Sicherheit und Verträglichkeit der Phytotherapeutika überwiegend als 'sehr gut' bis 'akzeptabel' bewertet.

10.1055/a-2279-5045 View study →

The impediment to action advances action. — Marcus Aurelius